Common Mistakes in Trial Results Reporting and How to Fix Them

Introduction: Importance of Accurate Results Reporting

Accurate reporting of clinical trial results on public registries such as ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) is a regulatory and ethical obligation. However, due to differences in data structure, formatting requirements, and limited internal QC, sponsors often make avoidable mistakes. These can lead to public queries, regulatory penalties, or inspection findings.

This article outlines the most common reporting errors and provides practical guidance on how to detect, correct, and prevent them using compliance-driven processes and quality checks.

Error 1: Participant Flow Inconsistencies

One of the most common issues is mismatch in the number of participants reported in the CSR vs. the registry’s participant flow section. Often, dropout counts, group allocation numbers, or “not treated” status are either omitted or misclassified.

Example: A sponsor reports 300 participants enrolled in the CSR, but only 285 are listed under “Started” in the ClinicalTrials.gov table, triggering a discrepancy flag.

Fix Strategy: Maintain a mapping file between raw dataset, CSR participant flow section, and registry summary. Ensure consistent terminology across all outputs. Use auto-validation tools within the Protocol Registration and Results System (PRS) to check totals.

Error 2: Baseline Data Incompleteness

Missing demographic or baseline characteristics can undermine the interpretability of outcomes. For example, failing to report gender breakdown or mean age per arm is a common error in CTIS uploads.

Corrective Action: Create a results summary template that includes mandatory fields as per registry specifications. Implement baseline checks within your medical writing review SOPs to ensure completeness prior to upload.

Error 3: Outcome Measure Discrepancies

This occurs when primary or secondary outcome measures listed in the registry do not match the final values presented in the CSR or are inconsistent across platforms. Even small shifts in timepoints, units, or populations analyzed can raise compliance issues.

Preventive Measure: Lock the protocol outcome definitions and registry fields early. Train teams on consistent use of endpoint terminology. Use the same SAS output table structure for both CSR and registry to reduce discrepancies.

Example Mapping Table

Error 4: Adverse Events Underreporting

Adverse events (AEs) are frequently misreported or incompletely disclosed due to complexity in coding and threshold application. CT.gov requires separate reporting of serious and non-serious AEs, both overall and per arm, with incidence thresholds. Failure to meet these standards can trigger public flags.

Correction Plan: Use MedDRA-based listings and confirm AE frequencies meet the reporting threshold (e.g., ≥5%). Validate that the CSR AE summary matches registry counts. Use PRS preview to verify expected tabular structure.

Error 5: Redaction and Data Privacy Violations

When posting lay summaries or results in the public domain, companies often neglect to remove sensitive personal data. Redaction errors can include naming trial sites, exposing investigator initials, or disclosing rare AE narratives that could lead to patient reidentification.

Compliance Action: Implement a two-level redaction review (medical and legal) before publishing. Use standard templates and refer to the EMA’s redaction guidance under Policy 0070. Consider using AI-powered redaction tools integrated into your disclosure platform.

CAPA Strategy for Disclosure Errors

When a significant registry error is discovered (e.g., underreporting of deaths, incorrect outcome values), implement a formal Corrective and Preventive Action (CAPA) procedure. A standard CAPA workflow involves:

1. Documenting the nature of the error and when it was identified.
2. Analyzing the root cause (e.g., version mismatch, training gap, miscommunication).
3. Updating the result fields with correct values.
4. Retraining involved teams on registry specifications.
5. Monitoring future uploads through QC checklists.

For examples of SOPs and CAPA templates, refer to PharmaSOP.in.

QA and Audit-Ready Processes

To maintain inspection readiness, QA teams should perform periodic audits of posted results. The checklist may include:

• Review of posting deadlines and actual upload dates
• Consistency check between CSR, registry, and protocol-defined endpoints
• Verification of PRS or CTIS validation success messages
• Archival of screenshots and system logs for audit trail

Additionally, establishing disclosure quality metrics—such as error rate per upload or cycle time from CSR finalization to public posting—can support continuous improvement initiatives.

Regulatory Trends and Inspection Insights

Agencies like the FDA and EMA are increasingly focusing on result disclosure accuracy during inspections. FDA Form 483 observations have cited inconsistencies between protocol-specified outcomes and posted summaries. The EMA also requires alignment of CTIS results with Module 5 documents of the Marketing Authorisation Application (MAA).

According to FDA guidance on ClinicalTrials.gov reporting, noncompliance can lead to notices of non-submission and potential civil monetary penalties. Early planning, clear roles, and checklists are essential to avoid such findings.

Conclusion

Inaccurate results reporting can have far-reaching implications—from regulatory penalties to loss of public trust. Understanding common mistakes such as data mismatches, baseline gaps, AE underreporting, and redaction errors is the first step. The second is establishing robust SOPs, QC workflows, and training modules for registry submissions.

By treating results disclosure as an integrated part of CSR and regulatory operations—not a post-hoc administrative task—sponsors can ensure transparency, compliance, and audit readiness. Tools like checklist-driven disclosure portals, redaction workflows, and cross-functional team training will form the cornerstone of future-ready disclosure strategy.

For further guidance, explore tools and regulatory harmonization documents at EMA or visit ClinicalStudies.in for real-world examples.

How to Avoid Common Mistakes in ClinicalTrials.gov Submissions

Introduction: Why Accuracy on ClinicalTrials.gov Matters

Registering a clinical trial on ClinicalTrials.gov is more than a formality—it’s a legal, ethical, and scientific responsibility. Inaccurate or incomplete entries can delay your study’s visibility, lead to regulatory penalties, and even jeopardize journal publication. This tutorial breaks down the most common errors flagged by the Protocol Registration and Results System (PRS) Quality Control (QC) reviewers and offers practical tips to ensure your submission is compliant and promptly approved.

Error #1: Incorrect or Incomplete Outcome Measures

One of the top reasons for PRS QC rejection is vague or missing outcome measure details. Common mistakes include:

• Missing time frames for primary and secondary outcomes
• Using non-specific titles like “efficacy” instead of “Change in HbA1c from baseline at Week 12”
• Failing to describe how the outcome is measured (e.g., “VAS score range 0–10”)

Each outcome must include a clearly defined title, a measurable time frame, and a description of the analysis method or tool. For instance:

Primary Outcome: “Mean change in systolic blood pressure from baseline to Day 28, measured in mmHg using ambulatory monitoring.”

Error #2: Poor Study Design Classification

Incorrect designation of study type, allocation, masking, and intervention model leads to frequent rejections. You must correctly specify:

• Study Type: Interventional, Observational, or Expanded Access
• Allocation: Randomized vs Non-Randomized
• Intervention Model: Parallel, Crossover, Factorial, etc.
• Masking: Open Label, Single, Double, Quadruple

Make sure this information matches your protocol. For example, a Phase II randomized placebo-controlled trial should not list “Single Group Assignment.” Reference FDA’s classification standards if unsure.

Error #3: IRB Status and Oversight Inconsistencies

Another frequent issue is IRB approval status mismatches. Sponsors often mark a study as “Recruiting” before receiving ethics approval. This is non-compliant and triggers flags. Ensure that:

• IRB approval is documented before updating the status to “Recruiting”
• Oversight authority is listed correctly (e.g., “United States: FDA”)
• FWA numbers or exemption justifications are available if requested

Incorrect IRB information can delay the public posting of your trial. Review your IRB submission before completing this field.

Error #4: Using Generic or Placeholder Text

Entries like “study drug,” “to be determined,” or “N/A” in critical fields (intervention name, eligibility criteria) are automatic rejections. You must specify:

• Intervention Name: Use the INN (generic) or proprietary name
• Eligibility: Provide inclusion/exclusion criteria in bullet format
• Facilities: Use actual site names and not “TBD”

Placeholder data is only acceptable during drafting. Remove all generic language before submission. Refer to SOPs available at PharmaSOP.in for formatting templates.

Error #5: Failure to Update Recruitment and Site Data

Even after initial submission, many sponsors neglect to update recruitment status, site locations, and contact information. This leads to:

• Outdated public records visible to patients and HCPs
• Noncompliance with FDAAA 801 and 42 CFR Part 11
• Journal editors flagging incomplete registry entries

Set reminders for quarterly reviews of registry data. Update fields such as:

• Recruitment Status – Not yet recruiting, Active, Completed
• Facility Addresses – Including contact emails and PI names
• Start and Completion Dates – Align with protocol amendments if changed

Accurate recruitment data reflects trial credibility and supports patient enrollment efforts.

Error #6: Responsible Party Misidentification

Designating the wrong responsible party is a legal issue. The responsible party must have regulatory authority and either be:

• The Sponsor
• A Principal Investigator (with agreement from sponsor)
• A designated Sponsor-Investigator

Common missteps include assigning administrative staff, CROs without delegated authority, or using generic “study admin” roles. PRS QC will return the record and flag it. Also, ensure the contact email is monitored routinely.

Error #7: Inconsistencies Between Protocol and Registry Data

Discrepancies between your IRB-approved protocol and registry entry invite scrutiny. Ensure consistency in:

• Study Title – Must match the protocol verbatim
• Outcome Measures – Reflect exactly what’s in Section 3 of the protocol
• Eligibility Criteria – Copied as-is from protocol synopsis or appendix

Reviewers compare uploaded documents and PRS entries side-by-side. Use a checklist or delegate to a qualified regulatory coordinator to avoid mismatches. See live protocol-to-registry comparison templates on ClinicalStudies.in.

Error #8: Skipping Validation or Preview Steps

PRS provides a validation tool that checks for formatting issues, missing data, and inconsistency flags. Sponsors often skip this step and submit directly, leading to QC returns. Always:

• Run “Validate” before each major change
• Preview public view to catch formatting errors
• Use “Save and Release” feature with caution—once released, QC review begins immediately

Errors at this stage delay your registry record from being visible and may trigger compliance notices. Regular internal reviews can save hours of QC back-and-forth.

Checklist for Error-Free ClinicalTrials.gov Entry

• ✅ Accurate and complete outcome measures
• ✅ Correct study design elements
• ✅ No placeholder or generic text
• ✅ Matching IRB approval status
• ✅ Updated site and contact information
• ✅ Validated entries using PRS tools

Adopt an internal SOP for registry review and assign responsibilities clearly. This aligns your trial with global transparency mandates and prevents costly delays.

Conclusion

Avoiding common ClinicalTrials.gov entry errors ensures your trial is discoverable, ethically transparent, and legally compliant. By understanding and correcting issues such as mismatched outcomes, incorrect study design fields, and IRB status misreporting, you improve the integrity of your trial record and its readiness for publication or inspection.

For real-time examples and FDA’s enforcement updates, visit FDA.gov or explore registry case studies at PharmaRegulatory.in.